Category Archives: ARV

  1. FEM PrEP Study Releases Trial Results

    via MedPage Today, by Ed Susman Pre-exposure prophylaxis with antiretroviral drugs failed to prevent women in Africa from becoming infected with human immunodeficiency virus (HIV) – apparently because more than half the women failed to take their medication. The incidence of HIV infection among previously uninfected women treated with a co-formulation of emtricitabine and tenofovir (Truvada) was Read More >>

    Africa, ARV, ARVs, clinical trials, FEM-PrEP, PrEP, South Africa, sub-saharan Africa
  2. Fenway Releases PrEP Policy Paper

    viaFenway Health Pre-exposure chemoprophylaxis (PrEP)—taking antiretroviral medications to prevent HIV transmission—could be a “game changer” for HIV prevention. PrEP has demonstrated partial efficacy with men who have sex with men (MSM), transgender women, and heterosexuals in several recent studies. Recent modeling of PrEP implementation coupled with scaled up treatment predicts that PrEP could significantly reduce HIV incidence Read More >>

    antiretroviral therapy, ARV, Fenway community healthhiv prevention, HIV/AIDS. pre-exposure prophylaxis, MSM, pre-exposure prophylaxis, PrEP
  3. Beliefs associated with unprotected sex are changing among gay men in Australia

    via Aidsmap, by Roger Pebody A study of Australian gay men examining unprotected sex and the beliefs that are associated with it has found that the concept of ‘treatments optimism’ needs to be unpacked. While some men do think that having HIV is less serious than it used to be, there is more of an association between Read More >>

    ARV, Australia, gay men, MSM, risk, Treatment, unprotected sex
  4. Behavioral or Biomedical… Or both?!

    via gaycitynews.com, by Perry N. Halkitis, Ph.D., M.S “But is this radical shift from the behavioral to the biomedical the right course of action for all of us?   For me there are two bigger issues — one which I will fully address here, and the other to which I will allude.” Despite our best attempts over Read More >>

    ARV, biomedical, PrEP, sexual behavior, Treatment as Prevention
  5. Microbicides 2012 Abstract and Scholarship Deadlines – November 17 (Aussie time)

      Heads up IRMA, you have little more than a week to submit abstracts and apply for scholarships for the Microbicides 2012 conference scheduled for April 15 – 18, 2012 in Sydney, Australia. Please take special note of the time – as Nov 17 in Australia could very well be Nov 16 where you are. Here is Read More >>

    ARV, biomedical, Microbicides, Microbicides 2012, new prevention technologies, PrEP, Sydney
  6. ‘Funding gap’ imperils science exploits, AIDS forum hears

    Via AFP, by Richard Ingham. “Science is running much faster now than what we can implement and what we can pay for.” The four-day Rome conference, ending Wednesday, heard the outcome of several landmark trials. The biggest found that giving early drug therapy to people with HIV reduced the risk of infecting others by a massive 96 Read More >>

    antiretroviral therapy, ARV, funding, HIV/AIDS, HIV/AIDS policy, IAS 2011, PrEP
  7. From ‘What if’ to ‘What Now’: Implementing the New Prevention Technologies

    Via AIDSMap, by Gus Cairns. Two consecutive sessions at the sixth International AIDS Society conference in Rome yesterday were devoted, now we have convincing scientific data on the benefits of treatment as prevention and PrEP, to putting these new prevention methods into practice. “We have moved from ‘What if?’ to ‘What now?’” was the comment of Mitchell Read More >>

    ARV, ARVs, cure, Dr. Anthony Fauci, HIV/AIDS, HIV/AIDS policy, IAS, IAS 2011, new prevention technologies, Rome, Treatment as Prevention
  8. Investment in HIV Prevention Research

    A report released yesterday by HIV Vaccines and Microbicides Resource Tracking Working Group at the IAS conference in Rome “found that overall investment in HIV prevention R&D had actually increased, with the modest exception of a one percent decline in vaccine R&D. The report documented a total US$1.19 billion investment in research and development (R&D) for four key HIV prevention Read More >>

    antiretroviral therapy, ARV, ARVs, circumcision, drug development, HIV/AIDS, IAS 2011, Microbicides, PrEP, rectal microbicide, research, vaccine, vaginal microbicide
  9. IAS 2011: Day 2 Press Release

    OFFICIAL PRESS RELEASE – DAY 2 16.30 (CET), MONDAY JULY 18 Antiretroviral Treatment is HIV Prevention: The proof is here Leading researchers and international experts to discuss the policy and prevention implications of three groundbreaking trial results: the HPTN O52 study, the Centers for Disease Control and Prevention TDF2 study and the University of Washington Partners PrEP Read More >>

    antiretroviral therapy, ARV, ARVs, Dr. Anthony Fauci, HIV/AIDS, HIV/AIDS policy, IAS, IAS 2011, new prevention technologies, prevention, Rome, Treatment as Prevention
  10. Microbicide Trials Network Statement On The Partners PrEP Study And The CDC’s TDF2 Study: VOICE Study Will Continue

    Via Medical News Today. Researchers from two major HIV prevention trials announced favorable results of an approach called oral pre-exposure prophylaxis, or PrEP. One of these trials, the Partners PrEP Study, has provided the strongest evidence yet of PrEP’s effectiveness. Information from both studies will need to be fully evaluated before it can be determined what impact Read More >>

    ARV, ARVs, HIV, HIV transmission, Microbicides, new prevention technologies, PrEP, prevention, rectal microbicide, Tenofovir, Truvada, vaginal microbicide